Vaxart, Inc. (NB11.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 08:05AM CEST. Market open.
| Previous close | 0.7915 |
| Open | 0.7825 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.7825 - 0.7825 |
| 52-week range | 0.5044 - 1.3320 |
| Volume | |
| Avg. volume | 424 |
| Market cap | 138.376M |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5300 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.50 |
- GuruFocus.com
Vaxart Inc (VXRT) Q1 2024 Earnings Call Transcript Highlights: Promising Developments and ...
Explore key financial outcomes, clinical trial updates, and strategic plans from Vaxart's latest earnings call.
GlobeNewswireVaxart Provides Business Update and Reports First Quarter 2024 Financial Results
Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart’s oral pill vaccine candidate to protect or reduce the effect of the disease in infants Expects to initiate Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator as early as the second quarter of 2024 Anticipates meeting with the FDA in mid-2024 to evaluate clinical data and discuss next steps for its norovirus program Conference call today a
© 2024 Yahoo. All rights reserved.